Dr. A. Armstrong's Key Takeaways for PsO. TNFi - great in PsA and pregnancy IL-17i - robust PsO efficacy and in PsA IL-23i - robust in PsO, fewer injections, and efficacious in PsA. #RNL2024 @RheumNow @_AprilArmstrong https://t.co/j8LaOGITuf

• https://twitter.com/uptoTate/status/1751301105231749582/photo/1

Did you know of all the small oral molecules, #apremilast is the only one approved for all stages of #psoriasis (mild to severe)? - Dr. Armstrong polls the audience on their thoughts then revealing the correct answer #RNL2024 @rheumnow https://t.co/NXSiaaGp3p

• https://twitter.com/KDAO2011/status/1751294420266156232/photo/1

Dr. A. Armstrong shares dermatology/dermatologist trends in PsO. 1. They tend to shorted then interval between injections as opposed to the amount of medication per dose. 2. Derms generally wait 6 months to switch meds 3. Like rheums, derms tend to switch classes (of tx agent)… https://t.co/HWbJMwnwkE https://t.co/bgKw7ynANN

• https://twitter.com/i/web/status/1751294126190993849
• https://twitter.com/uptoTate/status/1751294126190993849/photo/1
• https://twitter.com/uptoTate/status/1751294126190993849/photo/1

How are dermatology colleagues may frame our treatment options @_AprilArmstrong . This is helpful to consider in light of shared care discussions. The lack of love for JAKi in particular. @RheumNow #RNL2024 https://t.co/pv5EFXsXjI

• https://twitter.com/RichardPAConway/status/1751293742126870743/photo/1

When it comes to skin, this is how derms think and there is data to support this. - Dr. Amstrong on how IL-17i and IL23i are preferred over TNFi #psoriasis #RNL2024 @rheumnow https://t.co/UZWNgOljRh

• https://twitter.com/KDAO2011/status/1751292711712203170/photo/1

Welcome to the "FDA-approved" team Bimekizumab. Dr. Armstrong shows MOA of IL17a and IL17f dual inhibition, and the important PASI scores showing 2/3 of pts clear by week 16. @RheumNow #RNL2024 https://t.co/5ygHgOTfW8

• https://twitter.com/uptoTate/status/1751292468081897597/photo/1
• https://twitter.com/uptoTate/status/1751292468081897597/photo/1

Dermatologic approach to choosing treatment in psoriatic disease. The presence of psoriatic arthritis is an initial branch point and why co-management is so crucial in these patients @_AprilArmstrong @RheumNow #RNL2024 https://t.co/m26WiEUmPI

• https://twitter.com/RichardPAConway/status/1751292231988683107/photo/1

#RNL2024 @RheumNow @_AprilArmstrong Bimekizumab: IL-17A and IL-17F dual efficacy, unlike the prior IL-17i drugs - Fast onset - High efficacy with 2/3 PASI 100 by wk 16 (BE READY) https://t.co/cKh7j4KBs9

• https://twitter.com/ericdeinmd/status/1751291988945592477/photo/1

"We are setting a new standard for the skin, PASI100" -Dr. A Armstrong on the goal of treatment for #psoriasis. #TigerMom @rheumnow #RNL2024

In a patient with purely skin limited plaque psoriasis without systemic involvement, what would you choose for treatment? The rheum audience poll at #RNL2024 is all over the place in their choice! Dr. Armstrong lectures on how derms think about #psoriasis @rheumnow https://t.co/4YxaJPlpa5

• https://twitter.com/KDAO2011/status/1751291550179410226/photo/1

#RNL2024 @RheumNow @_AprilArmstrong Choosing a biologic in Psoriasis TNF - great in PsA, pregnancy. Avoid in demyelinating, hep B IL-17 - robust skin, PsA (axial too). Avoid in IBD IL-23 - robust skin, PsA evidence, fewer injections https://t.co/9Xt7Nx1tKq

• https://twitter.com/ericdeinmd/status/1751291264899653847/photo/1

Dr. April Armstrong shares a beautiful picture around pathophysiology in PsO/PsA, as demonstrated in a non-joint graphic below. "Consider the domains when choosing biologics." #RNL2024 @RheumNow https://t.co/4AtbEhysyA

• https://twitter.com/uptoTate/status/1751291067872223414/photo/1

Derms are thinking like rheums now! Dr. April Armstrong noted most derms digging below the surface to assess pts with psoriasis for systemic diseases to help them to choose systemic treatments. @rheumnow #RNL2024 https://t.co/7HTmiA6m4L

• https://twitter.com/KDAO2011/status/1751289830661595262/photo/1

EULAR guidelines and GRAPPA guidelines are moving closer to each other in treatment approaches - @AlexisOgdie @rheumnow #RNL2024 https://t.co/wtp57s28Bz

• https://twitter.com/KDAO2011/status/1751287866104119507/photo/1

EULAR 2019 PsA treatment guidelines, as detailed in 2023 presented by @AlexisOgdie We are starting to see EULAR and GRAPPA guidelines complimenting each other with the caveat that EULAR tends to focus on oligo vs polyarticular, vs peripheral arthritis terminology in GRAPPA… https://t.co/K8gtI7Makm https://t.co/iK5x8hlIda

• https://twitter.com/i/web/status/1751287665608081849
• https://twitter.com/uptoTate/status/1751287665608081849/photo/1